All In Biotech

Drug Trial Radar · NCT02467270

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

283

Actual

Start

Jul 13, 2015

Primary completion

Apr 29, 2020

Study completion Apr 23, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.

Conditions

  • Myeloid Leukemia, Chronic, Chronic Phase

Interventions

  • PonatinibDrug

    Tablet, taken orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12Time frame: 12 months after the first dose of study treatment

Locations

86 sites in 21 countries. Site status is shown where the registry gives one.

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • Indiana Blood & Marrow Transplantation

    Indianapolis, Indiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Michigan Medicine

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • University of Minnesota Medical School

    Minneapolis, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center - New York

    New York, New York

  • NewYork-Presbyterian Weill Cornell Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic Taussig Cancer Institute Main Campus

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Abramson Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah

  • Fundaleu

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital General de Agudo Jose Maria Ramos Mejia

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Italiano La Plata

    La Plata, Buenos Aires, Argentina

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Princess Margaret Hospital - Toronto

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Saskatchewan Cancer Agency

    Regina, Saskatchewan, Canada

  • Hospital del Salvador

    Providencia, Santiago Metropolitan, Chile

  • Centro de Investigaciones Clinicas Vina del Mar

    Viña del Mar, Valparaiso, Chile

  • Fakultni Nemocnice Olomouc

    Olomouc, Czechia

  • Ustav Hematologie a Krevni Transfuze Praha

    Prague, Prague, Czechia

  • Aarhus University Hospital

    Aarhus C, \Aarhus, Denmark

  • Centre de Lutte Contre le Cancer - Institut Bergonie

    Bordeaux, Aquitaine, France

  • Centre Hospitalier Regional Universitaire de Lille

    Lille, Hauts-de-France, France

  • Centre Hospitalier Universitaire de Nancy Hopital de Brabois

    Vandœuvre-lès-Nancy, Lorraine, France

  • Institut Universitaire du Cancer de Toulouse Oncopole

    Toulouse, Midi-pyrenees, France

  • Center Hospitalier Universitaire d'Angers

    Angers, Pays de la Loire Region, France

  • Centre Hospitalier Universitaire de Nantes Hotel Dieu

    Nantes, Pays de la Loire Region, France

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, Poitou-charentes, France

  • Centre Hospitalier Universitaire de Nice Hopital l'Archet

    Nice, Provence-Alpes-Côte d'Azur Region, France

  • Charite Universitatsmedizin Berlin

    Berlin, Germany

  • Universitatsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Heidelberg

    Mannheim, Baden-Wurttemberg, Germany

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.